Financials

  • Market Capitalization 275.95 M
  • Employee 35
  • Founded 2008
  • CEO N/A
  • Website www.inhibikase.com
  • Headquarter Delaware, United States
  • FIGI BBG005TP2339
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-4.18
Relación precio/flujo de caja
53.93

Related tickers

#NombrePrecio24h %7d %1M %1A %CapitalizaciónÚltimos 7 días
3389
MGNX
MacroGenics, Inc. - Common Stock
4.45 USD-1.11%-5.12%+12.37%+183.44%282.86 M USD
3398
SABS
SAB Biotherapeutics, Inc. - Common Stock
3.66 USD-1.88%-6.63%+6.40%+51.24%279.86 M USD
3410
GLSI
Greenwich LifeSciences, Inc. - Common stock
18.74 USD+0.92%-8.14%-23.26%+75.30%275.07 M USD
3433
SRZN
Surrozen, Inc. - Common Stock
22.73 USD-0.35%-2.99%-5.21%+167.10%263.90 M USD

Noticias